Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of durcabtagene autoleucel (BCMA-directed CAR-T) in relapsed/refractory multiple myeloma
2023-507140-37-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of durcabtagene autoleucel in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Best overall response (BOR) and overall response rate (ORR). Started Jul 2024; status: completed.
02
Drugs
durcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507140-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507140-37-00.